Clinical trial
Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic…
NCT00144859 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00144859 |
|---|---|
| Title | Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD) |
| Official title | A 28-day, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Anti-inflammatory Effect and Steady-state Pharmacokinetics of SB-681323 7.5 mg Per Day in Patients With Chronic Obstructive Pulmonary Disease. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive, Chronic Obstructive Pulmonary Disease (COPD) |
| Intervention type | Drug |
| Interventions | SB681323 |
| Enrollment | 82 |
| Start date | Jul 1, 2005 |
| First posted | Sep 5, 2005 |
| Last update posted | Jun 4, 2012 |
| Countries | Denmark, Finland, Germany, Netherlands, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: